Renal involvement in primary antiphospholipid syndrome

Wilson WA, Gharavi AE, KoikeT Lockshin MD, Branch DW, Piette JC, Brey R, Derksen RA et al (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42:1309–1311 Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DE Groot PG et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295–306 Cervera R, Piette JC, Font J, Shoenfeld Y, Camps MT, Jacobsen S, Lakos G, Tincani A et al (2002) Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum 46:1019–1027 Cervera R, Khamashta MA, Shoenfeld Y, Camps MT, Jacobsen S, Kiss E, Zeher MM, Tincani A et al (2009) Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 68(9):1428–1432 Nayfe R, Uthman I, Aoun J, Saad Aldin E, Merashli M, Khamashta MA (2013) Seronegative antiphospholipid syndrome. Rheumatology 52:1358–1367 Petri M (2000) Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun 15:145–151 Meroni PL, Borghi MO, Raschi E, Tedesco F (2011) Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol 7(6):330–339 Ramesh S, Morrell CN, Tarango C, Thomas GD, Yuhanna IS, Girardi G, Herz J, Urbanus RT et al (2011) Antiphospholipid antibodies promote leukocyte–endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via β2GPI and apoER2. J Clin Invest 121:120–131 Vega-Ostertag M, Liu X, Kwan-Ki H, Chen P, Pierangeli S (2006) A human monoclonal antiprothrombin antibody is thrombogenic in vivo and upregulates expression of tissue factor and E-selectin on endothelial cells. Br J Haematol 135:214–219 Cuadrado MJ, Buendía P, Velasco F, Aguirre MA, Barbarroja N, Torres LA, Khamashta M, López-Pedrera C (2006) Vascular endothelial growth factor expression in monocytes from patients with primary antiphospholipid syndrome. J Thromb Haemost 4:2461–2469 Giannakopoulos B, Krilis SA (2013) The pathogenesis of the antiphospholipid syndrome. N Engl J Med 368:1033–1044 Fischetti F, Durigutto P, Pellis V, Debeus A, Macor P, Bulla R, Bossi F, Ziller F et al (2005) Thrombus formation induced by antibodies to β2-glycoprotein I is complement dependent and requires a priming factor. Blood 106:2340–2346 Pierangeli S et al (2005) Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 52:2120–2124 Amigo MC, Garcia-Torres R, Robles M, Bochicchio T, Reyes PA (1992) Renal involvement in primary antiphospholipid syndrome. J Rheumatol 19:1181–1185 Sinico RA, Cavazzana I, Nuzzo M, Vianelli M, Napodano P, Scaini P, Tincani A (2010) Renal involvement in primary antiphospholipid syndrome: retrospective analysis of 160 patients. Clin J Am Soc Nephrol 5:1211–1217 Nochy D, Daugas E, Droz D, Beaufils H, Grunfeld JP, Piette JC, Bariety J, Hill G (1999) The intrarenal vascular lesions associated with primary antiphospholipid syndrome. J Am Soc Nephrol 10:507–518 Asherson RA, Cervera R, de Groot PG, Erkan D, Boffa MC, Piette JC, Khamashta MA, Shoenfeld Y, Catastrophic Antiphospholipid Syndrome Registry Project Group (2003) Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 12(7):530–534 Cervera R, Rodrıguez-Pinto I, Espinosa G on behalf of the Task Force on Catastrophic Antiphospholipid Syndrome (2014) Catastrophic antiphospholipid syndrome: task force report summary. Lupus 23:1283–1285 Ruffatti A, Tonello M, Cavazzana A, Bagatella P, Pengo V (2009) Laboratory classification categories and pregnancy outcome in patients with primary antiphospholipid syndrome prescribed antithrombotic therapy. Thromb Res 123:482–487 Pengo V, Denas G, Padayattil SJ, Zoppellaro G, Bison E, Banzato A, Hoxha A, Ruffatti A (2015) Diagnosis and therapy of antiphospholipid syndrome. Pol Arch Med Wewn 125(9):672–677 Galli M, Luciani D, Bertolini G, Barbui T (2003) Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome:a systematic review of the literature. Blood 101(5):1827–1832 Andreoli L, Chighizola CB, Banzato A, Pons-Estel GJ, de Jesus GR, Erkan D (2013) Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Arthritis Care Res 65(11):1869–1873 De Laat B, Derksen RH, Reber G, Musial J, Swadzba J, Bozic B, Cucnik S, Regnault V et al (2011) An international multicentre-laboratory evaluation of a new assay to detect specifically lupus anticoagulants dependent on the presence of anti-beta2-glycoprotein autoantibodies. J Thromb Haemost 9(1):149–153 Pengo V, Banzato A, Denas G, Jose SP, Bison E, Hoxha A, Ruffatti A (2013) Correct laboratory approach to APS diagnosis and monitoring. Autoimmun Rev 12:832–834 Moroni G, Ventura D, Riva P, Panzeri P, Quaglini S, Banfi G, Simonini P, Bader R, Meroni PL, Ponticelli C (2004) Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis. Am J Kidney Dis 43:28–36 Mehrani T, Petri M (2011) IgM anti-β2 glycoprotein I is protective against lupus nephritis and renal damage in systemic lupus erythematosus. J Rheumatol 38:450–453 Kincaid Smith P, Fairley KF, Kloss M (1988) Lupus anticoagulant associated with renal thrombotic microangiopathy and pregnancy-related renal failure. Q J Med 69:795–815 Scolari F, Savoldi S, Costantino E, Spitti C, Franceschini F, Tardanico R, Morassi L, Maiorca R (1993) Antiphospholipid syndrome and glomerular thrombosis in the absence of overt lupus nephritis. Nephrol Dial Transpl 8:1274–1276 Saracino A, Ramunni A, Pannarale G, Coratelli P (2005) Kidney disease associated with primary antiphospholipid syndrome: clinical signs and histopathological features in an case experience of five cases. Clin Nephrol 63(6):471–476 Fakhouri F, Noel LH, Zuber J, Beaufils H, Martinez F, Lebon P, Papo T, Chauveau D et al (2003) The expanding spectrum of renal diseases associated with antiphospholipid syndrome. Am J Kidney Dis 41:1205–1211 Pérez Velásquez C, Isenberg D, Croca S (2013) Secondary antiphospholipid syndrome nephropathy and lupus nephritis: a case-control study [abstract THU0308]. Ann Rheum Dis 72(Suppl. 3):270 Daugas E, Nochy D, Huong DL, Duhaut P, Beaufils H, Caudwell V, Bariety J, Piette JC, Hill G (2002) Antiphospholipid syndrome nephropathy in systemic lupus erythematosus. J Am Soc Nephrol 13:42–52 Tektonidou MG, Sotsiou F, Nakopoulou L, Vlachoyiannopoulos PG, Moutsopoulos HM (2004) Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and longterm outcome. Arthritis Rheum 50:2569–2579 D’Agati VD (2007) Renal disease in systemic lupus erythematosus, mixed connective tissue disease, Sjogren’s syndrome, and rheumatoid arthritis. In: Jennette JC, Olson IL, Schwartz MM, Silva FG (eds) Heptinstall’s pathology of the Kidney, 6th edn. Lippincott Williams & Wilkins, Philadelphia, pp 517–612 Banfi G, Bertani T, Boeri V, Faraggiana T, Mazzucco G, Monga G, Sacchi G (1991) Renal vascular lesions as a marker of poor prognosis in patients with lupus nephritis. Am J Kidney Dis 18:240–248 Moss KE, Isenberg DA (2001) Comparison of renal disease severity and outcome in patients with primary antiphospholipid syndrome, antiphospholipid syndrome secondary to systemic lupus erythematosus (SLE) and SLE alone. Rheumatology (Oxford) 40:863–867 Sangle SR, D’Cruz DP, Abbs IC, Khamashta MA, Hughes GR (2005) Renal artery stenosis in hypertensive patients with antiphospholipid (Hughes) syndrome: outcome following anticoagulation. Rheumatology (Oxford) 44:372–377 Tektonidou MG (2009) Renal involvement in the antiphospholipid syndrome (APS)-APS nephropathy. Clin Rev Allergy Immunol 36:131–140 Sciascia S, Cuadrado MJ, Khamasta M, Roccattello D (2014) Renal involvement in antiphospholipid syndrome. Nat Rev Nephrol 10:279–289 Vaidya S, Wang CC, Gugliuzza C, Fish JC (1998) Relative risk of post-transplant renal thrombosis in patients with antiphospholipid antibodies. Clin Transplant 12(5):439–444 Wagenknecht DR, Becker DG, LeFor WM, McIntyre JA (1999) Antiphospholipid antibodies are a risk factor for early renal allograft failure. Transplantation 68(2):241–246 Friedman GS, Meier-Kriesche HU, Kaplan B, Mathis AS, Bonomini L, Shah N, DeFranco P, Jacobs M et al (2001) Hypercoagulable states in renal transplant candidates: impact of anticoagulation upon incidence of renal allograft thrombosis. Transplantation 72(6):1073–1078 Eikelboom JW, Weitz JI (2014) The mTORC pathway in the antiphospholipid syndrome. N Engl J Med 371(4):369–371 Chighizola CB, Ubiali T, Meroni PL (2015) Treatment of thrombotic antiphospholipid syndrome: the rationale of current management—an insight into future approaches. J Immunol Res 2015:951424. doi:10.1155/2015/951424 Sciascia S, Naretto C, Rossi D, Bazzan M, Roccatello D (2011) Treatment-induced downregulation of antiphospholipid antibodies: effect of rituximab alone on clinical and laboratory features of antiphospholipid syndrome. Lupus 20:1106–1108 Korkmaz C, Kabukcuoglu S, Isiksoy S, Yalcin AU (2003) Renal involvement in primary antiphospholipid syndrome and its response to immunosuppressive therapy. Lupus 12:760–765 Ruiz-Irastorza G et al (2011) Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus 20:206–218 Erkan D, Aguiar CL, Andrade D, Cohen H, Cuadrado MJ, Danowski A, Levy RA, Ortel TL et al (2014) 14th International Congress on Antiphospholipid Antibodies Task Force report on antiphospholipid syndrome treatment trends. Autoimmun Rev 13(6):685–696 Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J, Laskin C, Fortin P, Anderson D et al (2003) A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 349:1133–1138 Finazzi G, Marchioli R, Brancaccio V, Schinco P, Wisloff F, Musial J, Baudo F, Berrettini M et al (2005) A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 3:848–853 Coloma Bazan E, Donate Lopez C, Moreno Lozano P, Cervera R, Espinosa G (2013) Discontinuation of anticoagulation or antiaggregation treatment may be safe in patients with primary antiphospholipid syndrome when antiphospholipid anti-bodies became persistently negative. Immunol Res 56(2–3):358–361 Criado-Garcıa J, Fernandez-Puebla RA, Lopez Jimenez L, Velasco F, Santamarıa Blanco-Molina MA (2008) Anticoagulation treatment withdrawal in primary antiphospholipid syndrome when anticardiolipin antibodies become negative. Rev Clin Esp 208(3):135–137 Erkan D, Aguiar CL, Andrade D, Cohen H, Cuadrado MJ, Danowski A, Levy RA, Ortel TL et al (2014) 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev 13(6):685–696 Noel N, Dutasta F, Costedoat-Chalumeau N, Bienvenu B, Mariette X, Geffray L, Sene D, Chaidi RB et al (2015) Safety and efficacy of new oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome. Autoimmun Rev 14(8):680–685 Cohen H, Doré CJ, Clawson S, Hunt BJ, Isenberg D, Khamashta M, Muirhead N, Trial Protocol Collaborators RAPS (2015) Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE. Lupus 24(10):1087–1094 Erkan D, Willis R, Murthy L et al (2014) A prospective open-label pilot study of fluvastatin on pro-in flammatory and pro-thrombotic biomarkers in antiphospholipid antibody positive patients. Ann Rheum Dis 73(6):1176–1180 Khattri S, Zandman-Goddard G, Peeva E (2012) B-cell directed therapies in antiphospholipid antibody syndrome—new directions based on murine and human data. Autoimmun Rev 11(10):717–722 Erkan D, Vega J, Ramon G, Kozora E, Lockshin MD (2013) Rituximab in antiphospholipid syndrome (RITAPS)—a pilot open-label phase II prospective trial for non-criteria manifestations of antiphospholipid antibodies. Arthritis Rheum 65:464–471 Berman H, Rodrıguez-Pinto I, Cervera R et al (2013) Rituximab use in the catastrophic antiphospholipid syndrome descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev 12(11):1085–1090